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ABSTRACT
The modified base 5-methylcytosine (m
5C) is well
studied in DNA, but investigations of its prevalence
in cellular RNA have been largely confined to
tRNA and rRNA. In animals, the two m
5C methyl-
transferases NSUN2 and TRDMT1 are known to
modify specific tRNAs and have roles in the
control of cell growth and differentiation. To map
modified cytosine sites across a human transcrip-
tome, we coupled bisulfite conversion of cellular
RNA with next-generation sequencing. We
confirmed 21 of the 28 previously known m
5C sites
in human tRNAs and identified 234 novel tRNA
candidate sites, mostly in anticipated structural
positions. Surprisingly, we discovered 10275 sites
in mRNAs and other non-coding RNAs. We
observed that distribution of modified cytosines
between RNA types was not random; within
mRNAs they were enriched in the untranslated
regions and near Argonaute binding regions. We
also identified five new sites modified by NSUN2,
broadening its known substrate range to another
tRNA, the RPPH1 subunit of RNase P and two
mRNAs. Our data demonstrates the widespread
presence of modified cytosines throughout coding
and non-coding sequences in a transcriptome,
suggesting a broader role of this modification in
the post-transcriptional control of cellular RNA
function.
INTRODUCTION
The presence of 5-methylcytosine (m
5C) in DNA and its
role as an epigenetic marker of genome activity is well
established (1–3). This has been facilitated in large part
by the ease of its detection using bisulﬁte sequencing,
which involves chemical conversion of cytosine (but not
m
5C) to uracil (4–6). While DNA is relatively devoid of
other modiﬁcations, 109 modiﬁcations have been
identiﬁed in different classes of RNA across all three
domains of life (7). tRNA is a particularly heavily
modiﬁed RNA class, and m
5C sites have been identiﬁed
in numerous archaeal and eukaryotic tRNAs, commonly
around the variable region and the anticodon loop. The
modiﬁcation has been shown to stabilize tRNA secondary
structure, affect aminoacylation and codon recognition,
and confer metabolic stability (8–13). m
5C sites are also
found in rRNA where they play roles in translational
ﬁdelity and tRNA recognition (14). Interestingly, work
that led to the discovery of the mRNA cap structure
also detected a low level of internal m
5C in mammalian
mRNA (15) and viral RNAs infecting mammalian cells
(16–18), although speciﬁc m
5C sites were not mapped
and the methylation was not corroborated by all studies
at the time (19–23). More recently, it was reported that the
methyl-CpG binding protein 2(MECP2) associates with
RNA and can regulate mRNA splicing (24,25) and that
reprogramming of cells to pluripotency can be achieved
using m
5C and pseudouridine-modiﬁed mRNAs encoding
the four Yamanaka factors (26). These observations
have reignited interest in the occurrence and function of
m
5C in mRNA and other non-coding RNA.
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5C methyltransferases (MTases) have been shown
tocatalyzethem
5CmodiﬁcationofeukaryoticRNA.First,
NCL1/TRM4 (Nuclear protein 1/tRNA–speciﬁc MTase 4)
is responsible for all known m
5C sites in yeast tRNA (27),
however its human ortholog NOP2/Sun domain protein 2
[(NSUN2); also known as Misu (28,29)] may have a much
narrower target range, selectively methylating the wobble
position of tRNA
Leu(CAA) prior to intron splicing (30).
Secondly, TRDMT1 (tRNA aspartic acid MTase 1, also
known as DNMT2), has been shown to methylate
position 38 on tRNA
Asp(GUC) in eukaryotes (12,31,32),
and tRNA
Val(AAC) and tRNA
Gly(GCC) in Drosophila (12).
TRDMT1 was previously thoughttoact asaDNA MTase;
however, it is now primarily regarded as an RNA MTase
(33). The range of RNA targets for these two enzymes in
animals are largely unexplored (34). Importantly, NSUN2
is cell cycle-regulated (35), directly targeted by MYC
(myelocytomatosis viral oncogene homolog) and
implicated in cancer cell proliferation (28). NSUN2
knockout mice are small and have revealed a role of the
enzyme in balancing stem cell self-renewal and differenti-
ation(36).LossofTRDMT1enzymaticactivityinzebraﬁsh
alsoleadstoreducedbodysizeandimpaireddifferentiation
of speciﬁc tissues (37). Of note, the anticancer drug
5-azacytidine was shown to prevent TRDMT1-dependent
cytosine methylation of tRNA
Asp(GUC) (38). These obser-
vations suggest that cytosine methylation in RNA is
important to the control of cell growth and differentiation,
thus motivating global screens for the occurrence of m
5C
in RNA.
Herein we have devised a method for transcriptome-
wide detection of modiﬁed cytosine residues at single
nucleotide resolution by combining RNA bisulﬁte con-
version with next-generation sequencing. We report that
RNA cytosine modiﬁcation pervades the human tran-
scriptome: we discovered over ten thousand novel candi-
date sites in mRNAs and various non-coding RNA types
that are distributed in non-random patterns. Furthermore,
we show that known and novel sites appear largely
dependent on the m
5C-speciﬁc MTase NSUN2. These
data represent the ﬁrst high-resolution view of cytosine
modiﬁcation across a transcriptome and provide a basis
for exploration of its biological signiﬁcance for mRNA
and non-coding RNA function.
MATERIALS AND METHODS
Unless otherwise stated below, all kits and reagents
were used according to the manufacturer’s instructions.
Cell culture and RNAi-mediated methyltransferase
knockdown
HeLa cells were cultured in DMEM supplemented with
10% FBS (both GIBCO-Invitrogen), and incubated with
5% CO2 at 37 C. Total RNA was extracted from
cells using TRIzol (Invitrogen). For RNAi-mediated
knockdown of DNMT1, TRDMT1 and NSUN2, cells
were transfected with siGenome SMART pool siRNAs
or a non-targeting control pool (Dharmacon) using
Lipofectamine RNAiMAX transfection reagent
(Invitrogen). Cells were passaged and transfected again
72h post-initial transfection. RNA was harvested from
cells 6 days post-initial transfection. For veriﬁcation of
knockdown, 1mg of total RNA was used for cDNA
synthesis with the SuperScript III Reverse Transcriptase
kit (Invitrogen). Real-time PCR was performed using
SYBR Green I Master (Roche) on a LightCycler
480 (Roche) instrument and results were analysed
using Relative Quantiﬁcation Software (Roche).
Oligonucleotides used for real-time PCR are listed in
Supplementary Table S1.
RNA isolation, and bisulﬁte conversion of RNA
Resuspended RNA was treated with DNase (Ambion),
and then phenol/chloroform extracted and re-precipitated
with ethanol. The RNA was then enriched for mRNA by
two iterations of oligo-dT-selection on magnetic beads
using an mRNA isolation kit (New England Biolabs).
Brieﬂy, 100mg of the total HeLa RNA was incubated
with 200pmol of biotin-(dT)18 conjugated to streptavidin
magnetic beads (New England Biolabs). The sample was
washed, eluted and then resubjected to the same process,
followed by rRNA depletion using the RiboMinus
TM kit
(Invitrogen). About 4mg of the mRNA-enriched sample
was subjected to bisulﬁte treatment, after addition of
400pg of in vitro transcribed Renilla luciferase (R-Luc)
RNA (39) as a negative control and 4ng of total HeLa
cell RNA to ensure tRNA representation in the sample.
Bisulﬁte conversion of RNA was performed as previ-
ously described (40), with the following modiﬁcations.
About 4mg of RNA was mixed in 100ml of 40%
sodium bisulﬁte (Sigma), 600mM hydroquinone (Sigma)
solution (pH 5.1) and incubated at 75 C for 4h. The
reaction mixture was then desalted by two passages
through Micro Bio-spin 6 chromatography columns
(Bio-Rad). RNA was desulfonated by adding an equal
volume of 1M Tris (pH 9.0) to the reaction mixture and
incubated for 1h at 75 C, followed by ethanol
precipitation.
Conventional bisulﬁte sequencing
A 220 ng aliquot of bisulﬁte-converted RNA was
converted to cDNA using random hexamers and the
Superscript III Reverse Transcriptase kit (Invitrogen).
PCR conditions were optimized for each respective
primer set (Supplementary Table S2) and the target
products were isolated from primers and spurious
products by agarose gel electrophoresis followed by
band excision and puriﬁcation using a Gel Extraction
Kit (Qiagen). Amplicons were ligated into the pGEM-T
Easy Vector system (Promega) and individual clones
sequenced to determine bisulﬁte conversion efﬁciency of
selected RNAs.
Novel m
5C candidate sites were veriﬁed using new
batches of HeLa cell total RNA. Where indicated,
negative control transcripts corresponding to the local
sequence around the candidate site were generated by
in vitro transcription and spiked into the HeLa cell
RNA to guard against non-conversion artefacts due to
RNA sequence or structure. Brieﬂy, multiple gene
5024 Nucleic Acids Research, 2012,Vol.40, No. 11constructs were generated from unconverted HeLa cell
cDNA to contain a stretch of sequence surrounding
selected candidate m
5C sites and ﬂanked by unique
priming sequences. Amplicons were cloned using the
pGEM-T Easy Vector system (Promega) and used as
templates for in vitro transcription using the
MEGAscript high yield transcription kit (Ambion).
Transcribed RNA was puriﬁed using MEGAclear
columns (Ambion) and 400pg of each in vitro transcript
was spiked into HeLa cell total RNA (4mg). The pool of
RNA was then DNase treated, bisulﬁte-converted and
conventionally sequenced as described above.
Oligonucleotides used to generate in vitro transcription
constructs and sequencing clones are listed in
Supplementary Table S2.
Library preparation and SOLiD
TM sequencing of
bisulﬁte-converted RNA
To ensure decapping and phosphorylation of the 50 end of
the RNA, 500ng of the bisulﬁte-converted sample was
treated with ﬁve units of Tobacco Acid Pyrophosphatase
(Epicentre Biotechnologies) at 37 C for 45min followed
by phenol/chloroform extraction. The sample was then
subjected to T4 Polynucleotide Kinase (New England
Biolabs) treatment and subsequent phenol/chloroform
extraction. A next-generation sequencing library was
prepared using the SOLiD
TM Whole Transcriptome
Analysis kit (Applied Biosystems). Since the sample was
already sufﬁciently fragmented by the bisulﬁte-conversion
reaction, the RNA fragmentation step prior to adaptor
hybridization and ligation was not performed. cDNA
with an approximate insert length of 50–120nt were
selected by polyacrylamide gel electrophoresis. Beads
were prepared, deposited and sequenced on a SOLiD
TM
Version 3 instrument (Applied Biosystems). Sequenced
read data was deposited in the National Center for
Biotechnology Information sequence read archive (acces-
sion number SRA027832.1).
Sequenced read mapping and analysis
Sequenced reads were mapped against reference sequences
consisting of all known human transcripts from the
Ensembl v61 database (mRNA, rRNA, tRNA, mitochon-
drial RNA and all non-coding RNA) (41), predicted and
known tRNA sequences obtained from the GtRNAdb
(42) and tRNAdb (43), miRNA hairpin sequences from
miRBase v16 (44), rRNA sequences obtained from the
NCBI RefSeq database, and R-Luc spike-in negative
control sequences (Supplementary Table S3). A ‘CCA’
sequence was appended to tRNAs lacking one since this
non-templated addition is common to tRNA sequences.
To reduce mapping ambiguity, identical sequences
were collapsed and represented only once in the reference.
Sequenced reads were mapped using the SOCS-B
program (45), an alignment tool designed to map
bisulﬁte-converted SOLiD
TM colour-space reads to
nucleic acid reference sequences. This program disregards
mismatches between ‘C’ in the reference and ‘T’
introduced in reads as a result of bisulﬁte conversion.
SOCS-B mapping parameters were chosen such that
low-quality reads (average quality across a read <18)
and reads with ambiguous colour-call represented by ‘.’
in the colour-space sequence were discarded. During
mapping, up to four colour-space mismatches were
allowed between the reference and read sequences to
accommodate sequencing errors and natural variation.
Given the large proportion of ‘predicted’ tRNA sequences
in the reference, reads multi-mapping to both known and
predicted tRNA sequences were preferentially assigned to
the known tRNA sequence. For all other reads, SOCS-B
was set to assign multi-mapping reads to a single
randomly selected mapped locus. Reads mapping to the
anti-sense strand of the reference were discarded.
Identiﬁcation of modiﬁed cytosine sites in RNA
Non-conversion of a cytosine in read sequences was taken
to indicate the presence of m
5C. To delimit m
5C site
prediction to high conﬁdence candidates, threshold
parameters were set to a read coverage  10 and con-
version rate  80% per cytosine position in the reference
(see ‘Results’ section). Read coverage was deﬁned as
the number of reads that overlap a given cytosine. The
following equation describes the conversion rate
calculations.
Number of reads representing non   conversion ðCÞ
at a given cytosine position ¼ i,
Number of reads representing conversion ðTÞ
at a given cytosine position ¼ j
Conversion rate ¼ð j   100Þ=ði+jÞ
Read coverage and cytosine conversion rate were
calculated directly from mapped data for tRNA, rRNA
and R-Luc spike-in negative control sequences. For all
other RNA types, cytosine-mapping data was transferred
to genomic coordinates before applying threshold criteria
(Supplementary Figure S1). Ensembl Perl API v61 was
used for coordinate transfers from transcript sequence
to the human genome assembly version GRCh37 (hg19).
Analysis of modiﬁed cytosine location bias within the
transcriptome
Enrichment of non-converted sites across genomic regions
was computed by chi-squared and binomial tests, relative
to the proportion of all potential sites (cytosines with read
coverage  10) in each measured category. Enrichment of
methylation sites for regulatory elements was estimated by
overlap with the 30-UTR structural RNA prediction set of
(46) (binomial test relative to the proportion of structured
to unstructured nucleotides in 30UTR).
Enrichment of non-converted sites near binding regions
for Argonaute (I–IV) and Pumilio 2 proteins was
estimated by overlapping site coordinates with the
PAR-CLIP dataset of (47) mapped as described in (48).
Putative RNA binding protein (RBP) binding sites here
deﬁned as regions with more than one PAR-CLIP read.
P-value of enrichment was computed by permutation test
against a shufﬂed set of positions within each genomic
region. A plot of RBP binding site density in the vicinity
Nucleic Acids Research, 2012,Vol.40, No. 11 5025of the m
5C sites was computed by averaging a 2000bp
window centred on all methylation sites.
RESULTS
A transcriptome-wide survey of m
5C candidate sites in
human RNA
To develop a method for single nucleotide mapping of
m
5C sites in a cellular transcriptome we adapted an
RNA bisulﬁte conversion protocol, originally devised for
primer extension-based detection of m
5C (40), for use with
a sequencing-based readout (see ‘Materials and Methods’
section for details). As in DNA bisulﬁte sequencing, sites
of m
5C in RNA will be read as cytosine in cDNA
sequence, while unmodiﬁed cytosines will appear as thy-
midine. Although some other types of modiﬁed cytosine
can also be resistant to bisulﬁte treatment (see ‘Discussion’
section), for simplicity we refer in the following to sites
of non-conversion as ‘m
5C candidate sites’. We chose to
analyse RNA preparations from HeLa cells (a human
cervical cancer cell line) and used both positive and
negative control RNAs to monitor success of the pro-
cedure. Our positive control was the endogenous
tRNA
Asp(GUC), which harbours three previously identiﬁed
m
5C sites at structural positions 38, 47 and 48 (7,31,32).
Our negative control was in vitro transcribed Renilla
luciferase (R-Luc) mRNA lacking m
5C, which was
spiked into the cellular RNA sample prior to bisulﬁte
treatment. An aliquot of this RNA was used for conven-
tional bisulﬁte sequencing reactions to examine the
expected m
5C patterns in our controls. The R-Luc
negative control RNA exhibited virtually complete
cytosine conversion (Figure 1A; 99.8% conversion
overall), while all three known m
5C sites in
tRNA
Asp(GUC) selectively displayed low levels of conver-
sion (Figure 1B; position 38 and 48: 0%, position 47:
12.5% conversion). These results showed that our RNA
conversion protocol was efﬁcient and accurate detection
of m
5C sites is achieved.
We then performed SOLiD
TM next-generation
sequencing of the converted RNA sample and obtained
 96 million sequence reads (50nt in length).
Approximately 41 million reads could be mapped to a
custom human transcriptome reference (described in the
‘Materials and Methods’ section) using the SOCS-B
program (45) and allowing up to four colour-space
mismatches without counting those resulting from a
C to T sequence change (indicative of bisulﬁte conver-
sion). We next analysed the coverage and extent of
conversion at cytosine residues in our controls, setting
successively more stringent cut-offs, from four to
zero-mismatch (4–0mm) mapping data. Our controls
had sufﬁcient coverage across cytosines and displayed
the expected C to T conversion patterns (Figure 1C and
D show results for 2mm data; see also Table 1 and
Supplementary Table S4). R-Luc RNA showed almost
complete C to T conversion overall (e.g. 99.5% at 2mm;
Figure 1C), and no individual position showed less than
90% conversion at a coverage threshold of 10 irrespective
of the number of mismatches allowed. The three known
m
5C sites in tRNA
Asp(GUC) showed low levels of con-
version; this was consistent at all stringencies of
mapping (e.g. 17.9% at 2mm; average across all three
A B
C D
Figure 1. Single-nucleotide resolution mapping of m
5C candidate sites in RNA. HeLa cell RNA preparations were spiked with a trace amount of
in vitro transcribed R-Luc RNA and bisulﬁte-converted as detailed in the ‘Materials and Methods’ section. (A) Negative control R-Luc and (B)
endogenous tRNA
(AspGUC) as a positive control were ﬁrst analyzed by conventional sequencing to establish the efﬁcacy of bisulﬁte conversion
(top panels; columns signify cytosine positions along the RNA sequence, rows represent individually sequenced alleles, open boxes indicate cytosine
to uracil conversion read as thymidine in cDNA and ﬁlled boxes indicate a retained cytosine). Numbers below refer to cytosine positions in the
primary RNA sequence. Nucleotide positions highlighted in red designate previously identiﬁed m
5C sites in tRNA
(AspGUC). Dual axis charts (bottom
panels) display next-generation sequencing data mapped at 2mm for the same control RNAs. Blue bars represent bisulﬁte-induced cytosine
conversion, while red lines represent read coverage across individual residues. Top and bottom panels are aligned to each other by interrogated
cytosine residues.
5026 Nucleic Acids Research, 2012,Vol.40, No. 11sites; Figure 1D). These data indicate that our combin-
ation of bisulﬁte conversion with next-generation
sequencing can accurately detect m
5C sites in RNA, and
importantly, has a low false-positive rate.
Discovery of novel m
5C candidate sites
We next examined all reads mapping to cytoplasmic and
mitochondrial tRNA sequences. There are 28 known m
5C
sites in human tRNAs (43) and 27 of these were detectable
in our dataset with at least one read spanning the site
(Supplementary Dataset S1, Supplementary Table S5).
Conﬁrming our approach, we called the large majority
of these sites as modiﬁed when applying a C to T conver-
sion threshold of  80% and read coverage of  10 (Figure
2A; 21 sites called as modiﬁed, with 24 sites having sufﬁ-
cient coverage when allowing  1mm). We next extended
our analysis to all cytosines in tRNAs. To reduce over- or
under-calling of sites due to multi-mapping to highly
similar tRNA sequences, reads were preferentially
aligned to known tRNA sequences over predicted se-
quences (42,43). In animals, all known m
5C sites are
found at six discrete locations within the tRNA secondary
structure (see inset in Figure 2B) (7,34,43). Thus, we
posited that genuine novel m
5C candidate sites in
tRNAs should also be located primarily, if not exclusively,
at these positions and used this notion to further reﬁne the
parameters for novel m
5C site selection from our data.
Up to a conversion threshold of 60% we found  80%
or more of the novel candidate sites in these anticipated
positions across all mismatch datasets, but for those with
 2mm this proportion remained at this level up to a con-
version threshold of 80% (Figure 2B). Thus, taking into
account our analyses of both known and novel tRNA
sites, we deﬁned  80% C to T conversion and  10 read
coverage as suitable criteria to assign candidacy to novel
m
5C sites and applied them to reads mapped up to two
colour-space mismatches.
In total, we detected 255 modiﬁed cytosine candidate
sites in tRNA sequences using the above threshold
criteria (Table 1 and Supplementary Dataset S2). Of
these sites, 21 were previously known as m
5C in human
tRNAs, for 51 cases other human isodecoder tRNA
variants were known to harbour m
5C at those sites,
68 sites were reported as methylated in other animal
tRNA orthologs, while 115 sites were entirely novel
before this study.
Within rRNA sequences, we clearly detected two previ-
ously known m
5C sites at positions 3782 and 4447 in
human 28S rRNA (7,32). We independently veriﬁed
these sites as well as a site within the decoding centre of
12S mitochondrial rRNA (position 841; Supplementary
Figure S2) that was previously identiﬁed as m
5Ci n
hamster mitochondrial 12S rRNA (49,50). However, we
also saw several prominent clusters of non-conversion
(e.g. clusters of 10 or more sites in a 50-nt window,
Supplementary Dataset S2), particularly in the cytoplas-
mic and mitochondrial large subunit rRNAs, which are
among the longest, highly structured cellular RNAs.
AB
Figure 2. Deﬁning parameters for m
5C candidate site selection using tRNA data. (A) Plot of conversion against read coverage at 28 known m
5C
sites in human tRNAs (43). The majority of the previously identiﬁed tRNA m
5C sites had a conversion of 80% or less and read coverage of at least
10 (shaded area). (B) Dependence of the proportion of novel tRNA candidate sites in anticipated tRNA structural positions (red circles in tRNA
cloverleaf cartoon) on chosen conversion cut-off. Read coverage threshold was  10. Colour code for dots and lines refers to mapping at different
colour-space mismatch limits.
Table 1. Number of cytosine residues identiﬁed as m
5C in different RNA categories in 2mm data
RNA type # of Cytosine # of Cytosine with
 10 read coverage
#o fm
5C(  80%
conversion rate)
%m
5C
R-Luc 255 232 0 0.0
tRNA 14584 2943 255 8.7
mRNA 16785229 2247702 8495 0.4
Other non-coding RNA 5783482 144799 1780 1.2
Nucleic Acids Research, 2012,Vol.40, No. 11 5027These are likely due to incomplete denaturation of some
highly structured regions of RNAs, thus we did not
consider further our mapping data for rRNAs. Only
 7% of the m
5C sites seen in other cellular RNAs
occurred in such clusters, indicating a low proportion of
false positive m
5C predictions due to RNA structure in
our data.
We then applied our selection criteria to identify novel
m
5C candidate sites throughout the transcriptome. To
simplify the interpretation of results, we transferred the
cytosine mapping information for the remaining
RNA types to genomic co-ordinates and calculated
cytosine conversion and coverage for each genomic
locus. Approximately 2.4 million cytosine positions in
the genome corresponding to known transcripts were
covered by at least 10 reads, representing 10.6% of the
total cytosines in known transcripts. Of these, 10275
sites (0.43% of all assessed cytosines) were identiﬁed
with  80% conversion rate; 1863 sites remained when
applying the highly stringent requirement of  50% con-
version rate. Genomic coordinates, extent of conversion
and additional information on all identiﬁed sites are listed
in Supplementary Dataset S2. About 1780 of these sites
were present in a range of non-coding RNA types,
including lincRNA, pseudogenes and processed pseudo-
genes, while 8495 sites were located in mRNA sequences
(Table 1).
Validation of m
5C candidate sites by conventional bisulﬁte
sequencing
To validate our global site mapping data, we veriﬁed three
candidate sites from mRNAs, eight from tRNAs, and two
from other non-coding RNAs by conventional bisulﬁte
sequencing (Figure 3 and Supplementary Figures S2 and
S3). Among the selected sites there were six that had
been previously identiﬁed as m
5C in other animal
homologs (tRNA
Gly(UCC), 3 sites; tRNA
Lys(CUU), 1 site;
mitochondrial tRNA
Glu(UUC), 1 site; 12S mitochondrial
rRNA, 1 site). The three sites in mitochondrial
tRNA
Ser(GCU) were entirely novel, as those were chosen
in protein-coding mRNAs (cyclin-dependent kinase 2
interacting protein, CINP; nicotinate phosphoribosyl-
transferase domain containing 1, NAPRT1; NADH
dehydrogenase 1 beta subcomplex 7 mRNA, NDUFB7;
1 site each) and a non-coding RNA (RPPH1,
Ribonuclease P RNA component H1). To assess potential
non-conversion due to local RNA structure, we designed
and prepared in vitro transcribed negative control tran-
scripts mimicking the sequence context of ﬁve of the
sites to be veriﬁed. These negative controls were spiked
into independently prepared HeLa cell RNA prior to
bisulﬁte treatment. None of these negative controls
showed any evidence of non-conversion at the test sites,
whereas all sites except position 47 in tRNA
Gly(UCC were
convincingly conﬁrmed (Figure 3 and Supplementary
Figure S3). This demonstrated that most of the novel
m
5C candidate sites predicted by our next-generation
sequencing-based mapping are independently veriﬁable.
Identiﬁcation of NSUN2 and TRDMT1 dependent
m
5C sites
To gain insight into the enzymes mediating RNA methy-
lation, we performed RNAi-mediated knockdown of the
RNA methyltransferases TRDMT1 and NSUN2 by
AB C
Figure 3. Validation of novel m
5C candidate sites. Conventional bisulﬁte sequencing data is shown for three novel sites, (A) residue 48 in
tRNA
(LysCUU),( B) residue 174 in the RNase P RNA component H1 (RPPH1), and (C) residue 748 in cyclin-dependent kinase 2 interacting
protein mRNA (CINP). Top panels display results for endogenous transcripts. Data for spiked-in in vitro transcribed negative controls harboring
the same sequence ﬂanked by unique priming sites are also shown (middle panels) as are corresponding next-generation sequencing results (lower
panels). Numbering of cytosine positions is as described in Figure 1, positions highlighted in red designate m
5C sites identiﬁed by next- generation
sequencing. See Supplementary Figure 3 for additional validation data.
5028 Nucleic Acids Research, 2012,Vol.40, No. 11transient transfection of HeLa cells. Knockdown of the
DNA methyltransferase DNMT1 was used as a negative
control, with knockdown efﬁciency determined by quan-
titative RT–PCR (Supplementary Figure S4).
Conventional bisulﬁte sequencing of target regions in
tRNA
Asp(GUC) and tRNA
Leu(CAA) revealed marked dis-
appearance of known target m
5C sites for TRDMT1
(residue 38 in tRNA
Asp(GUC)) and NSUN2 (residue 34 in
tRNA
Leu(CAA)) in the respective knockdown cells
(Figure 4A and B). Furthermore, methylation of
residues 47 and 48 in tRNA
Asp(GUC) was also shown to
disappear with NSUN2 knockdown. Novel sites in CINP
and NAPRT1 mRNAs, and in the non-coding RPPH1,
were all clearly NSUN2-dependent (Figure 4C–E).
Two previously identiﬁed m
5C sites in 28S rRNA, as
well as two novel candidate sites in 12S mitochondrial
rRNA and tRNA
Lys(CUU) did not respond to either
enzyme knockdown (Supplementary Figure S2).
Modiﬁcations at these sites may be placed by other
MTases, or they may correspond to other cytosine modi-
ﬁcations that could protect against bisulﬁte conversion
(see ‘Discussion’ section); most likely these sites reside in
RNA species that are not turned over rapidly enough
to be amenable to assay in short-term knockdown
experiments. Of the 11 sites tested, we found that six
were dependent on NSUN2 and one was dependent on
TRDMT1, also corroborating the identity of the modiﬁ-
cation at these sites as m
5C. This further implies a major
role for NSUN2 in modifying the human transcriptome,
increasing the number of its known target sites from one
to six, and extending its substrate range to an additional
tRNA as well as a non-coding RNA and two mRNAs.
Analysis of m
5C location bias within the transcriptome
To discover the wider role of m
5C in the human transcrip-
tome, we searched our data for any bias in the location of
m
5C candidate sites. To this end, we considered a subset of
9177 sites residing in canonical transcripts (longest known
cDNA coding sequence; 89% of all predicted sites). The
distribution of m
5C candidate sites varied across different
RNA types (P-value <2.2 10
 16, chi-squared test). Sites
were signiﬁcantly enriched in a variety of non-coding
transcript types, including several pseudogene categories
(P-value <2.2 10
 16, binomial test), whereas they were
signiﬁcantly depleted in mRNA (P-value <2.2 10
 16,
binomial test) (Supplementary Table S6). Given that
many non-coding RNAs are expected to be of low abun-
dance, we deemed our dataset to be of insufﬁcient
coverage to further analyse the patterns of m
5C distribu-
tion in these RNA types. By contrast, despite being
relatively devoid of m
5C, candidate sites in mRNAs
constituted the great majority ( 83%) identiﬁed in our
screen. We therefore, searched for any bias in site distri-
bution within mRNA sequences. This revealed a signiﬁ-
cant enrichment within the untranslated regions (both
50 and 30 UTRs), and a relative depletion within coding
regions (P-value <2.2 10
 16, binomial test) (Figure 5A).
Gene ontology enrichment analysis using the elim method
(51) of genes harbouring m
5C candidate sites in different
transcript regions (30UTR, 50UTR and CDS) did not show
any statistically signiﬁcant enrichment at an FDR of 0.05
(data not shown).
A complementary approach to look for functional links
was to test for any spatial association between m
5C can-
didate sites and cis-acting regulatory motifs within RNA.
Thus, we overlaid our modiﬁcation mapping data with a
set of recently identiﬁed human regulatory RNA elements
within 30 UTRs (46). This showed a moderate but statis-
tically signiﬁcant enrichment of those elements in the
vicinity of m
5C sites (1.42-fold; P-value=0.04, binomial
test; data not shown). Furthermore, we overlaid our
mapping data with publicly available transcriptome-wide
maps of binding sites for major regulatory RNA-binding
proteins in human cells generated by PAR-CLIP-Seq (47).
This showed a substantial association of m
5C candidate
sites in mRNA with binding regions for the Argonaute
I-IV proteins (Figure 5B), the central components of the
miRNA/RISC complex ( 1.76-fold over 30UTR; P-value
<1 10
 3, permutation test) but, interestingly, not for
binding sites of another post-transcriptional regulator,
the Pumilio 2 protein (1.15 fold; P-value=0.13). We
also inspected the local sequence context for candidate
sites and saw an increased frequency of C and G as
ﬂanking bases and a depletion of U either side of the
modiﬁed cytosine, but no strict requirement for a targeting
context was evident (data not shown). While more
parsimonious analyses of subclasses of m
5C candidate
sites may yield further insight, it appears that m
5C
context requirements differ from those for m
6A where a
clear sequence context was reported [e.g. Gm
6A in yeast
(52)]. The enrichment patterns detailed above persisted
when the analyses were done with more stringently
selected candidate sites (i.e.  50% conversion rate), and
altogether they are highly suggestive of an involvement
of cytosine modiﬁcation in post-transcriptional gene
regulation.
DISCUSSION
Herein we described the successful combination of
bisulﬁte treatment with next-generation sequencing of a
cellular RNA library. This allowed us to survey the modi-
ﬁcation status of over two million cytosine sites in the
transcriptome of the human HeLa cell line, which led
to the mapping of over ten thousand novel candidate
m
5C sites in diverse types of cellular RNA (Table 1;
Supplementary Dataset S2). The accuracy of our
approach and site selection criteria was supported by
multiple tests, including veriﬁcation of a subset of
known and novel sites by conventional bisulﬁte
sequencing and m
5C MTase knockdown.
Some cytosine modiﬁcations other than m
5C may
also be resistant to bisulﬁte treatment, including
3-methylcytidine, N4-methylcytidine (m
4C), N4,2’-O-
dimethylcytidine (m
4Cm), and N4-acetylated variants.
Schaefer et al. (32) were able to detect m
4Cm at position
1402 of bacterial 16S rRNA by locus-speciﬁc bisulﬁte
sequencing. The equivalent region in mitochondrial 12S
rRNA from the hamster is methylated in the motif
‘Gm
4CCm
5CG’ (49,50). We surveyed the orthologous
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Figure 4. Analysis of methyltransferase target sites. HeLa cells were transfected with siRNAs targeting DNMT1, TRDMT1 and NSUN2 or a
non-targeting control siRNA (NTC) as indicated on the left. Conventional bisulﬁte sequencing data was obtained as described in Figure 1 and is
shown for (A) tRNA
Asp(GUC) (residue 38 is a known TRDMT1 target) and (B) tRNA
Leu(CAA) (residue 34 is a known NSUN2 target) (C) CINP and
(D) nicotinate phosphoribosyltransferase domain containing 1 (NAPRT1) mRNAs, and (E) RPPH1 non-coding RNA. Nucleotide positions high-
lighted in red below designate m
5C sites identiﬁed by next-generation sequencing. Green boxes indicate sites selectively responding to MTase
depletion. Hatched boxes indicate intronic sequence. See Supplementary Figure S4 for data on RNAi knock-down efﬁciency and Supplementary
Figure S2 for analysis of additional target sites.
5030 Nucleic Acids Research, 2012,Vol.40, No. 11region of the human counterpart by next generation and
conventional sequencing and could only detect the m
5C
site (Supplementary Figure S2). This may suggest that
human mitochondrial 12S rRNA does not carry
the m
4C modiﬁcation or that m
4C and m
4Cm display dif-
ferential sensitivity to bisulﬁte conversion. Perhaps, more
likely, it reﬂects differences in treatment protocols as used
by these colleagues and us. On balance, our evidence is
consistent with m
5C as the modiﬁcation underlying the
majority of novel candidates sites reported here,
although deﬁnitive proof for any given site would
require application of more elaborate direct detection
methods. Transcriptome-wide bisulﬁte sequencing of
material from cells depleted for speciﬁc MTases would
be a further tractable option to conﬁrm modiﬁcation
identity on a global scale. Our current method also has
limits with regard to surveying extremely structured
regions such as those found in rRNA, which are among
the longest, highly structured RNAs, so we excluded
suspect regions of rRNA from further analysis. In
addition, we included unmodiﬁed spike-in sequences in
our veriﬁcation efforts to control for effects of local struc-
ture (Figure 3), and veriﬁed sites through other means,
such as MTase knockdown (Figure 4). While this work
was in progress, Schaefer and colleagues used their
locus-speciﬁc bisulﬁte sequencing approach to detect
known m
5C sites in several tRNAs and rRNAs in different
contexts (12,32,38), further underscoring the validity and
scope of our transcriptome-wide method. Future efforts to
improve the method will focus on optimization of RNA
denaturation and conversion, while sufﬁciently preserving
RNA integrity.
Our study detected 255 candidate sites for cytosine
modiﬁcation in tRNAs, most of them not previously
mapped in humans. We found that most high-quality can-
didate sites were found at positions within tRNA second-
ary structure known to be occupied by m
5C in animals
(43) (Figure 2), broadly conﬁrming existing expectations
of the role of m
5C in modulating tRNA function (8–13).
Nevertheless, an emerging facet of tRNA biology is their
processing into smaller regulatory RNAs species (53),
and TRDMT1-mediated placement of m
5C has been
shown to protect several tRNAs against stress-mediated
cleavage in Drosophila (12). The present work thus
provides a wealth of mapped m
5C sites that can now be
assessed for a role in this phenomenon.
Human NSUN2 was thought to have a narrow
substrate range, possibly conﬁned to a single site within
tRNA
Leu(CAA) (30). In contrast, our evidence demon-
strates that its substrate range is likely to be much
broader, as it is responsible for modiﬁcation of fur-
ther sites in tRNA
Asp(GUC), the RNA subunit RPPH1 of
RNase P (54), and even mRNAs (Figure 4). The unex-
pected relationship between a tRNA-modifying and a
tRNA-processing enzyme is intriguing and experiments
will now have to address whether RPPH1 modiﬁcation
affects the enzymatic properties of RNase P. In support
of a broader role of NSUN2 in mRNA modiﬁcation it was
found to be among the most highly enriched proteins in an
in vivo capture screen for HeLa cell proteins binding to
polyadenylated RNA (A Castello & MW Hentze, personal
communication). NSUN2 is frequently overexpressed
in a number of different tumour types and varies in its
expression and intracellular localization (i.e. nucleolar
versus cytoplasmic) during the cell cycle, while its enzym-
atic activity is regulated by phosphorylation (28,35,55).
Importantly, it furthermore functions in balancing stem
cell self-renewal and differentiation (36). Given the
broad role for NSUN2 in modifying different RNA
types we uncovered here, it is thus plausible that aspects
of the transcriptome-wide RNA methylation patterns we
have observed are dynamically responding to, and/or sup-
portive of, distinct states of cellular growth, differentiation
and transformation. Comparative studies of differential
RNA methylation, particularly in the cancer and stem
cell contexts, and in cells depleted of the candidate RNA
MTases are now warranted.
A key outcome of this study was the clear demonstra-
tion of a widespread presence of m
5C within mRNAs.
Pioneering work in the 1970’s had suggested the
presence of m
5C, as well as N6-methyladenosine (m
6A)
in mRNA, but their low abundance combined with
a lack of suitable methods to map individual sites
hampered investigation of their relevance. The
AB
Figure 5. Analysis of bias in m
5C candidate site location within mRNA. (A) Histogram showing relative enrichment of m
5C sites in 30 UTR and
50 UTR compared to CDS (Error bars=95% conﬁdence interval; ‘Poisson’ distribution). (B) RNA-binding protein target density versus distance
from m
5C site in protein coding transcripts (CDS and UTR both). Conﬁdence bands are shown in grey (SEM).
Nucleic Acids Research, 2012,Vol.40, No. 11 5031identiﬁcation of the methyltransferase responsible for m
6A
in mRNA subsequently allowed progress in its investiga-
tion (e.g. 52,56), but work on m
5C in mRNA had all but
seized since then. We detected candidate sites for cytosine
modiﬁcation in several thousand mRNAs, indicating that
the presence of m
5C is not limited to a highly specialized
subset of mRNAs. Our analyses also indicate that m
5C
distribution within the transcriptome is not random, as
we found the modiﬁcation enriched within non-coding
RNAs, whereas functional mRNAs were relatively
devoid of it. Analyses of datasets with more complete
mRNA coverage will be required to more precisely map
the preferred locations of m
5C within mRNAs, as they will
likely hold clues to its molecular function(s). Our ﬁnding
of an enrichment of m
5C within the UTRs of mRNA and
in the vicinity of Argonaute protein binding regions,
already presents an intriguing pretext to further investi-
gate a role of m
5C in post-transcriptional gene regulation.
Possibilities include, but are not limited to, a role in
protecting mRNAs against innate antiviral defence
mechanisms (26) or promoting their efﬁcient translation,
as has been suggested for m
6A (52).
The potential of RNA editing and modiﬁcation to
further diversify functions of cellular transcriptomes
has recently come to the fore (57). We provided here
a ﬁrst global map of the patterns of m
5C modiﬁcation in
the human transcriptome, which link it to mechanisms of
post-transcriptional gene regulation and control of cell
growth and differentiation. Our approach to the
transcriptome-wide mapping of m
5C can now be utilized
to survey distribution patterns of this modiﬁcation in
different organisms and tissues, as well as to assess its
potential for dynamic change under different cellular
conditions.
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